DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ghosal hematodiaphyseal dysplasia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGhosal hematodiaphyseal dysplasia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ghosal hematodiaphyseal dysplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Ghosal hematodiaphyseal dysplasia is an autosomal recessive disorder caused by mutation in the TBXAS1 gene on chromosome 7q33.34. It presents in early childhood with moderate to severe anaemia, splenomegaly, a hypocellular marrow with increased reticulin, and diaphyseal and metaphyphyseal widening of long bones on X-ray. Two case series report a total of five patients who were successfully treated with chronic low-dose corticosteroid therapy, and a separate report describes a 20-month-old girl with severe transfusion-dependent anaemia who was treated with oral prednisolone and thereafter did well on steroid maintenance. In one series of three cases, all patients dramatically responded to oral steroid and no longer needed blood transfusion, requiring low-dose steroid for up to five years.
The anaemia in GHDD is consistently described as steroid-responsive, and timely treatment with steroids is said to reduce transfusion requirements and halt bone damage. However, the evidence rests entirely on small case reports and case series — the largest single series includes only three patients. No controlled trials exist. The long-term outcomes beyond five years of steroid therapy are not described, and the optimal dose, duration, and side-effect profile of chronic corticosteroid use in these children remain uncharacterised.
The condition is noted to have a notable incidence in the Indian subcontinent and Middle East, but population prevalence is unknown. Diagnosis is made by long-bone radiography and confirmed by genetic testing for TBXAS1 mutation. What is still missing is a systematic registry of patients, prospective data on steroid tapering and adverse effects, and any trial comparing steroid regimens or alternative treatments. Without these, the natural history and optimal management of GHDD remain defined only by anecdote.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric Blood & Cancer · 2010 · 23 citations
Ghosal hematodiaphyseal dysplasia: A rare cause of a myelophthisic anemia
AbstractGhosal hematodiaphyseal dysplasia syndrome (GHDD) is a rare clinical syndrome characterized by increased bone density and a severe, myelophthisic anemia. Few cases have been reported worldwide and there are no detailed descriptions of the associated hematologic abnormalities and long-term clinical outcomes after treatment. Here, we report two siblings with GHDD who were successfully treated with chronic, low dose, corticosteroid therapy. Although GHDD is uncommon, these cases illustrate the need to consider GHDD in patients with anemia and bone dysplasia and the use of chronic, low-dose steroid therapy.
Journal of Pediatric Hematology/Oncology · 2014 · 13 citations
Steroid-responsive Anemia in Patients of Ghosal Hematodiaphyseal Dysplasia
AbstractGhosal hematodiaphyseal dysplasia (GHDD) is a recently recognized cause of steroid-responsive anemia. We would like to report 3 cases of GHDD who presented in early childhood with moderate to severe anemia, splenomegaly, and a hypocellular marrow with increased reticulin. They were easily diagnosed with long-bone x-rays showing diaphyseal and metaphyseal widening and loss of diaphyseal constriction. All cases dramatically responded to oral steroid and no longer needed blood transfusion. They required steroid at low doses for long term (up to 5 y). GHDD is easy to diagnose with long-bone radiography and consistently responds to steroid. It should therefore be considered as a differential diagnosis of unusual anemia in early childhood, especially in children from the Middle East or the Indian subcontinent.
Journal of Tropical Pediatrics · 2024 · 2 citations
Steroid-responsive anemia with bony dysplasias: What lurks behind!
AbstractGhosal hematodiaphyseal dysplasia (GHDD) is an autosomal recessive disorder characterized by diaphyseal dysplasia of long bones, bone marrow fibrosis, and steroid-responsive anemia. Patients with this disease have a mutation in the thromboxane-AS1 (TBXAS1) gene located on chromosome 7q33.34. They present with short stature, varying grades of myelofibrosis, and, hence cytopenias. Patients with the above presentation were evaluated through clinical presentation, X-ray of long bones, bone marrow examinations, and confirmed by genetic testing. In this article, we present two cases: The first case is a 3-year-old boy who presented with progressive pallor and ecchymotic patches for a year. On investigation, he had bicytopenia and bone marrow fibrosis. His anemia was steroid responsive and was finally diagnosed as GHDD. The second case is a 20-month-old girl who presented with blood in stools, developmental delay, anemia, and increased intensity of long bones on X-ray. Since other investigations were normal, suspicion of GHDD was raised, and a genetic workup was conducted which suggested mutation in TBXAS1 gene, confirming the diagnosis of GHDD. Children with refractory anemia and cortical thickening on skeletogram should always be evaluated for dysplasias. Timely treatment with steroids reduces transfusion requirements and halts bone damage, thus leading to better growth and improved quality of life.
Pediatric Hematology and Oncology · 2003 · 1 citations
Early Manifestation of Ghosal-Type Hemato-Diaphyseal Dysplasia
AbstractGhosal-type hemato-diaphyseal dysplasia is a rare autosomal recessive disorder with distinctive diaphyseal and metaphyseal dysplasia of long bones and steroid-dependant anemia. The authors describe a 20-month-old girl who had had a severe transfusion-dependent anemia since late infancy and marked locomotion difficulties as a toddler. The diagnosis was established by X-ray bone survey. The anemia was treated with oral prednisolone. Since then, the patient has been doing well on steroid-maintenance therapy and has no more walking difficulties. The incidence of hemato-diaphyseal dysplasia in the Indian subcontinent and Middle East is notable.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
